Alzheimer’s Disease: Many Failed Trials so Where Do We Go from Here?
Symposium — Saturday, April 6, 2019 — 1:00 PM - 2:30 PM — Convention Center, Room W308CD
American Federation for Medical Research (AFMR) — Chair: Allison Reiss — Co-Chair: Mark Stecker
Alzheimer’s disease is a global burden with potentially devastating personal and social consequences. This symposium will address the need to identify possible disease-modifying therapies for Alzheimer’s dementia and provide up-to-date information on diagnosis through imaging and biomarkers. The decision by Pfizer to stop looking for new Alzheimer’s drugs followed by Eli Lilly and AstraZeneca’s recent discontinued drug trial is a huge setback in progress toward treatment for Alzheimer’s Disease. With no new drugs in over 15 years, we are at a crossroads. Do we continue to use our standard approaches? Do we target amyloid or turn elsewhere? Who will pick up the mantle and what comes next?
- Turning Failure into Success: What We Can Learn from the Drugs that Did Not Show Benefit
Mark Stecker — Neurology, UCSF Fresno
- Pathophysiology of Alzheimer's Disease: From Bench to Bedside
Allison Reiss — Medicine and Biomedical Research, NYU Winthrop Hospital
- Biomarkers for Alzheimer's Disease: Prediction to Prevent Progression
Benjamin Wolozin — Pharmacology and Neurology, Boston University School of Medicine